SUNPHARMA2020-04-012020-06-30in-bse-fin:OneOperatingExpenses01Member SUNPHARMA2020-04-012020-06-30in-bse-fin:OneOperatingExpenses02Member SUNPHARMA2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SUNPHARMA2020-04-012020-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUNPHARMA 2020-04-01 2021-03-31 2020-07-22 INR Crores First quarter Single segment Pharmaceutical 2020-04-01 2020-06-30 Unaudited Standalone 29630400000.00 211900000.00 29842300000.00 8494200000.00 2578200000.00 -552900000.00 4661900000.00 689000000.00 1427900000.00 7228800000.00 24527100000.00 5315200000.00 0.00 5315200000.00 -4300000.00 0.00 -4300000.00 0.00 5319500000.00 0.00 0.00 0.00 0.00 5319500000.00 8100000.00 5327600000.00 0.00 0.00 2399300000.00 1 2.22 2.22 0.00 0.00 2.22 2.22 Notes: n1. The above unaudited standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2020. n n2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. n n3. The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgements and estimates, including in relation to recoverability of receivables, assessment of impairment of goodwill and intangibles, investments and inventory, based on the information available to date, while preparing the Company’s financial results as of and for the quarter ended June 30, 2020. n n4. The Board of Directors of the Company at its meeting held on July 31, 2020, approved the Scheme of Amalgamation and Merger between the Company and Sun Pharma Global FZE (wholly owned subsidiary of the Company) which inter-alia, envisages merger of Sun Pharma Global FZE into the Company. The scheme shall be effective post receipt of required approvals and accordingly, the above results do not reflect the impact on account of the scheme. n n5. The Company has only one reportable segment namely 'Pharmaceuticals'. n n6. Figures for previous periods have been regrouped / reclassified wherever considered necessary. n n7. The figures for the quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to December 31, 2019, being the date of the end of third quarter of the financial year, which were subject to limited review by the Statutory Auditor of the Company. Net (gain) / loss on foreign currency transactions -561400000.00 Other expenses 7790200000.00